24,651 Shares in Embecta Corp. $EMBC Purchased by Fox Run Management L.L.C.

Key Points

• Fox Run Management L.L.C. acquired 24,651 shares of Embecta Corp., valued at approximately $314,000, during the 1st quarter of 2023.
• Embecta also announced a quarterly dividend of $0.15, yielding 4.4%, set to be paid on September 15th, 2023.
• The company reported earnings of $1.12 per share for the last quarter, exceeding analyst forecasts by $0.35, with revenues increasing by 8.4% year-over-year.

Fox Run Management L.L.C. bought a new position in shares of Embecta Corp. (NASDAQ:EMBC - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 24,651 shares of the company's stock, valued at approximately $314,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Deerfield Management Company L.P. Series C grew its stake in Embecta by 19.8% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 3,270,535 shares of the company's stock valued at $67,537,000 after purchasing an additional 540,192 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of Embecta in the fourth quarter worth $6,598,000. Jefferies Financial Group Inc. increased its stake in shares of Embecta by 60.1% in the first quarter. Jefferies Financial Group Inc. now owns 573,000 shares of the company's stock worth $7,306,000 after buying an additional 215,000 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Embecta by 382.9% in the first quarter. Russell Investments Group Ltd. now owns 262,541 shares of the company's stock valued at $3,347,000 after acquiring an additional 208,170 shares in the last quarter. Finally, Ancora Advisors LLC boosted its stake in Embecta by 275.9% during the 4th quarter. Ancora Advisors LLC now owns 254,156 shares of the company's stock valued at $5,248,000 after acquiring an additional 186,550 shares during the last quarter. Hedge funds and other institutional investors own 93.83% of the company's stock.

Embecta Stock Down 0.8%

NASDAQ EMBC traded down $0.12 during trading hours on Monday, hitting $14.26. The company had a trading volume of 371,592 shares, compared to its average volume of 741,565. The firm has a market cap of $834.07 million, a P/E ratio of 9.97, a price-to-earnings-growth ratio of 0.80 and a beta of 1.08. Embecta Corp. has a fifty-two week low of $9.20 and a fifty-two week high of $21.48. The business has a fifty day simple moving average of $11.04 and a 200-day simple moving average of $11.94.

Embecta (NASDAQ:EMBC - Get Free Report) last issued its quarterly earnings data on Friday, August 8th. The company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.35. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The firm had revenue of $295.50 million for the quarter, compared to the consensus estimate of $278.15 million. During the same period last year, the firm posted $0.74 EPS. Embecta's quarterly revenue was up 8.4% compared to the same quarter last year. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. Equities analysts forecast that Embecta Corp. will post 2.85 EPS for the current fiscal year.

Embecta Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, September 15th. Investors of record on Friday, August 29th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Friday, August 29th. Embecta's dividend payout ratio is 41.96%.

Analyst Upgrades and Downgrades

EMBC has been the subject of several research analyst reports. BTIG Research set a $25.00 target price on shares of Embecta and gave the stock a "buy" rating in a research report on Friday, May 23rd. Mizuho decreased their price target on Embecta from $13.00 to $12.00 and set a "neutral" rating for the company in a research note on Wednesday, July 16th. Finally, Wall Street Zen upgraded Embecta from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $19.00.

Embecta Company Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.